The ATMCF is a national drug discovery capability that applies medicinal chemistry expertise to translate biomedical research towards clinical relevance. Facilitated by Therapeutic Innovation Australia (TIA), and based at The Monash Institute of Pharmaceutical Sciences (MIPS), Parkville, the ATMCF collaborates with researchers to identify and synthesize bioactive compounds (small molecules) which are fed into medicinal chemistry optimization against a range of potency, selectivity and pharmacokinetic criteria.
The ATMCF provides Australian researchers with an opportunity to:
- access subsidised medicinal chemistry
- access the Therapeutic Innovation Australia (TIA) Pipeline Accelerator for further cost reductions
- work with a team of medicinal chemists who have a proven track record in drug discovery and commercialisation outcomes
Submission requirements & due date
- Applications must be submitted for internal review by 24 April 2020.
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an application to Research Services for review